|
|
 |
|
Viewing report
|
|
|
|
Emerging Drug Delivery Technologies & Strategies - Players, Pipelines & Partnerships
Espicom Business Intelligence Ltd, Sep 2011, Pages: 188
A major new 3-volume report from Espicom featuring:
- An examination of trends and advances in the three major drug delivery sectors
- Unique sales forecasts to 2020 for key products
- Critical analyses of 58 specialist developers driving the drug delivery market onwards
Increasingly, pharmaceutical companies are turning to drug delivery developers to overcome a range of challenges in getting novel new medicines and formulations effectively and safely delivered. Indeed, it can be argued that identifying an efficient delivery method is as important as the therapy itself. This new report assesses three key emerging sectors in the drug delivery field that will play a crucial role in tackling a range of delivery issues associated with these new classes of drugs in key therapeutic areas such as cancer, CNS, cardiology, respiratory and ophthalmology.
This report:
- Provides a detailed insight into the current and future market
- Provides an overview of the marketplace, outlining current thinking on the technologies being researched and employed
- Identifies key application areas
- Appraises currently available products which utilise advanced delivery platforms
- Examines new product developments from major specialist drug delivery companies, critically analysing their prospects
- Allows ready comparison on different technologies within a company's portfolio.
Use this report to:
- Assess the strengths and weaknesses of competing products/technologies in the context of specific delivery sectors and development companies
- Identify and review licensing and collaborative partners
- Understand the merits and applications of the main approaches being researched.
LIPID-BASED DELIVERY
Many new chemical entities are poorly water soluble which may affect a drug's bioavailability and efficacy. Advanced drug delivery systems using biocompatible lipid-based technologies can be used to improve solubility, increase bioavailability (enhance absorption) and efficacy, helping to reduce the level of drug dosage and decrease the incidence and severity of adverse effects.
To date more than a dozen products have been approved that utilise some of the first generation lipid-based technologies, pioneered by Elan Pharmaceuticals, Enzon, Gilead Pharmaceuticals, ALZA (acquired by Johnson & Johnson), Skye Pharma, and The Liposome Company (acquired by Elan Pharmaceuticals). These products encompass anaesthetics, antiinfectives and oncology agents and together generate over US$1.85 billion in sales annually.
POLYMER-BASED DELIVERY
Research activity is intensive and the top 20 drug delivery specialists are currently investigating more than 75 products in preclinical and clinical development; over half of these products (c.46 products) are likely to reach the market by 2020 to generate global sales in excess of US$2.6 billion by 2020.
The pharmaceutical industry has been utilising advanced polymer-based delivery technologies to improve the pharmacokinetics and targeted delivery of small and large molecule drugs.
To date more than two dozen products have been approved that utilise PEGylation technologies developed by some of the industry pioneers, such as ALZA, Endo Pharmaceuticals and Nektar Therapeutics. In addition, several specialists have developed controlled-release polymer matrix to prolong the release of active pharmaceutical ingredients in situ with technologies developed by Debiopharm Group and Durect.
By 2020 we forecast that nearly 60 novel polymer-based products could reach the market to generate global sales in excess of US$5 billion through improved pharmacokinetics of approved and new compounds, as well as the emergence of novel biologics, nucleic acidbased medicines and small molecule agents.
BIOVECTORS/GENE THERAPY/VACCINES
During the last twenty years there have been significant advances in the manufacture, development and delivery of gene therapies, RNA therapies and vaccines. No single biovector stands out for each field and many different development strategies have been adopted to optimise delivery.
Gene-related medicines have achieved limited success to date - no gene therapies have been approved and only a few antisense drugs have carved out a therapeutic niche in ocular diseases (Vitravene; CMV, Macugen; wet AMD). However, R&D investment for gene related products continues to grow at a fast rate and this highlights the challenges and opportunities which face developers, delivery technologists and regulators in this field.
In contrast, interest in the vaccine market has rocketed fuelled by biodefence programmes and the outbreak of avian influenza as well as advances in vaccine production technologies which has lowered the barrier to entry for the smaller players. Whilst infectious diseases, particularly influenza and HIV, remain a major area of interest, therapeutic vaccines are emerging to gain a share of the marketplace.
About the Author
Dr Cheryl L Barton is an independent consultant with over 18 years research and business analysis experience. Following her research positions in academia and seven years with Merck, Dr Barton joined investment bank ABN Amro NV as a senior equity analyst to provide coverage on pan-European companies, and assess the potential impact of new drug development on European Stocks. In 2002, Dr Barton founded PharmaVision to provide independent, tailor-made, life science and consumer health research.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
